Skip to content
sellWeak cluster of 210b5-1 plan

Suma Krishnan sold $9.0M of KRYS

President, R&D at Krystal Biotech, Inc.. 25,000 shares at an average of $359.32, traded Sep 4, 2026, filed Sep 4, 2026.

Warning score
33
Value
$9.0M
25,000 shares
Holdings after
1,302,145
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    President
    +20
  • Trade size
    $9.0M at market
    +25
  • Share of holdings sold
    Sold 1.9% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

KRYSOct 9, 2026 · close 331.61
Since filing Sep 4, 2026: -7.4%SPY +1.3% · excess -8.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001298711-26-000009, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-520$354.54$184k1,326,62538 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-2,006$355.57$713k1,324,61938 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-3,267$356.37$1.2M1,321,35238 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-3,962$357.57$1.4M1,317,39038 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-3,180$358.42$1.1M1,314,21038 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-3,392$359.39$1.2M1,310,81838 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-2,320$360.47$836k1,308,49838 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-1,242$361.61$449k1,307,25638 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-1,992$362.65$722k1,305,26438 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-565$363.34$205k1,304,69938 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-1,329$364.48$484k1,303,37038 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-826$365.41$302k1,302,54438 d ago
Sep 4, 2026SOpen-market sale
Common Stock10b5-1
-399$366.56$146k1,302,14538 d ago

Related signals

Other insiders at Krystal Biotech, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
38Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$9.0M
25,000 shares
-2%
38Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$5.4M
35,873 shares
-2%
33Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$5.4M
35,873 shares
-2%
38Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$2.1M
14,127 shares
-1%
33Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$2.1M
14,127 shares
-1%
45Moderate
KRYSsell 310b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$8.9M
50,000 shares
-3%
40Moderate
KRYSsell 310b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$8.9M
50,000 shares
-3%
6Weak
KRYSsell 310b5-1
Krystal Biotech, Inc.
Kathryn Romano
Chief Accounting Officer
$131k
750 shares
-6%
38Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Krish S Krishnan
President and CEO
$8.2M
50,000 shares
-3%
33Weak
KRYSsell 210b5-1
Krystal Biotech, Inc.
Suma Krishnan
President, R&D
$8.2M
50,000 shares
-3%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Suma Krishnan sold $9.0M of KRYS | InsiderTell